Value-Based Contracting: CMS Final Rule Leaves ‘Multiple Best Price’ Questions Unresolved
Implementation of ‘multiple best price’ reporting approach to facilitate value-based payment arrangements postponed until 2022 to allow time for further guidance to be developed, but new definition of VBP arrangements is effective in March.
You may also be interested in...
Energy and Commerce Committee made some changes to a Trump-era regulation designed to make it easier for manufacturers to enter into value-based drug pricing contracts with commercial payers to limit unintended consequences for Medicaid and Medicare, but most Democrats say the tweaks don’t outweigh the harms of codifying the regulation.
A House hearing on bipartisan drug pricing reform bills continues the intense focus on the role of pharmacy benefit managers. But it also shows continued interest in finding ways to make payment systems work for cutting edge gene therapies.
The demonstration project planned by the US Centers for Medicare and Medicaid Services is in keeping with past agency efforts to promote value-based contracts for cell and gene therapy.